Debevoise Advises Guggenheim and Goldman Sachs as Financial Advisors to Pfizer in Its $160 Billion Merger with Allergan

23 November 2015

Debevoise & Plimpton LLP is advising Guggenheim Securities and Goldman, Sachs & Co. as financial advisors to Pfizer Inc. in its $160 billion merger with Allergan plc. Pursuant to the terms of the merger agreement, the Allergan parent company will be the parent company of the combined group.

The completion of the transaction, which is expected in the second half of 2016, is subject to certain conditions, including receipt of regulatory approval in certain jurisdictions, including the United States and European Union, the receipt of necessary approvals from both Pfizer and Allergan shareholders, and the completion of Allergan’s pending divestiture of its generics business to Teva Pharmaceuticals Ltd., which Allergan expects will close in the first quarter of 2016.

The Debevoise team is led by partner Andrew L. Bab and includes partner Jeffrey J. Rosen and associates Christopher Anthony, Pankita D. Naik, Bridgette Parks and Katharine R. Steele.

Debevoise & Plimpton LLP is a premier law firm with market-leading practices, a global perspective and strong New York roots. We deliver effective solutions to our clients’ most important legal challenges, applying clear commercial judgment and a distinctively collaborative approach.